Copy Link Print Information

Vudalimab

(Synonyms: XmAb20717)
Customer Review

Based on 1 Customer Validation

Vudalimab is a potent dual PD-1 and CTLA-4 inhibitor as a fully humanized bispecific monoclonal antibody. Vudalimab targets immune checkpoint receptors PD-1 and CTLA-4 and promotes tumor-selective T-cell activation.

For research use only. We do not sell to patients.

  • Purity : ≥99.0%
  • CAS No.: 2329669-72-7
  • Molecular Weight:144.5 kDa
  • Storage:
    Shipping with dry ice

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Experimental Validation Results for Vudalimab
  • Experimental Validation Results for Vudalimab
  • Experimental Validation Results for Vudalimab
  • Vudalimab Chemical Structure
    Vudalimab Chemical Structure
CAS No.: 2329669-72-7
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Vudalimab Product Recommendations:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • Protocols
  • Purity & Documentation
  • References
  • Help & FAQs
Top Publications Citing

Use of MCE Products

Keywords

MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Register
Sign in to MedChemExpress
Register New Account

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • 1/16

    half-IGG1-kappa/(scFv-kappa-heavy)-h-CH2-CH3

  • 1/16

    Flow Cytometry analysis of Raji cells labelling CTLA4 (red) with Vudalimab (anti-CTLA4) (HY-P99166). Cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

  • 1/16

    Flow Cytometry analysis of THP-1 cells labelling PDCD1 (red) with Vudalimab (anti-PDCD1) (HY-P99166). Cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

  • Vudalimab Chemical Structure
    1/16
  • Vudalimab
  • Flow Cytometry analysis of Raji cells labelling CTLA4 (red) with Vudalimab (anti-CTLA4) (HY-P99166). Cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
  • Flow Cytometry analysis of THP-1 cells labelling PDCD1 (red) with Vudalimab (anti-PDCD1) (HY-P99166). Cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
  • half-IGG1-kappa/(scFv-kappa-heavy)-h-CH2-CH3